Celltrion’s cancer drug Vegzelma, a biosimilar referencing best-selling Avastin (bevacizumab), was approved for marketing from Britain’s Medicines and Healthcare products Regulatory Agency (MHRA), the Korean company announced on Monday.

The approval which came only a month after the European Commission’s authorization has been sought for all indications of Avastin, including metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and metastatic breast cancer.

Celltrion said it aims to establish Vegzelma in the global market with cost advantages. Celltrion Healthcare, in charge of sales and marketing, is planning to launch Vegzelma in major European countries in the second half of this year.

Celltrion filed for approval of the drug with the Ministry of Food and Drug Safety in Korea late year and the Food and Drug Administration (FDA) in the United States. The results are expected to be released within this year.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]